086450 — DongKook Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapHigh Flyer

Annual income statement for DongKook Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	482,280	559,103	594,193	661,647	730,994
Cost of Revenue
Gross Profit	290,835	337,410	350,260	379,826	410,781
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	413,696	474,370	530,974	588,994	664,120
Operating Profit	68,585	84,733	63,219	72,654	66,873
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	75,629	80,031	69,754	68,632	60,838
Provision for Income Taxes
Net Income After Taxes	59,050	57,880	52,916	54,757	48,871
Minority Interest
Net Income Before Extraordinary Items
Net Income	56,312	55,925	50,345	52,896	47,175
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	56,312	55,925	50,345	52,896	47,175
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,265	1,251	1,109	1,172	1,041
Dividends per Share